This website is for information purposes only. Use of our website is subject to your agreement to our disclaimer and terms and conditions. By closing (click "I agree") or leaving this box, you signify your agreement to these.
One of the hallmarks of the cancer cells is not able to splice various gene products effectively. Reduced activity of the gene RBM4 is associated with the inability of cancerous cells to make right products from a gene. SSHD-RBM4 molecule targets to optimise the function of RBM4.
What does RBM4 do?
The gene RBM4 encodes an RNA binding protein that plays an important role in making sure that all the right products are synthesised from a particular gene. Many genes are able to produce a number of different biological products by a process known as alternative splicing. The inability to splice various gene products effectively has now been recognised as one of the important hallmarks of cancer cells. In fact, recent studies have shown that reduced expression of RBM4 results in its inability to instruct cancer cells to kill themselves, control their proliferation, arrest tumour growth and inhibit migration or spread of cancer cells.
Reduced expression of RBM4 is also associated with poorer survival of cancer patients [1].
As a bonus, evidence indicates that RBM4 may also help by supporting the pancreas to produce insulin more readily [2].